Mereo BioPharma Group plc
No SEC Form 4 filings for $MREO in the last 30 days.
See all $MREO insider activity →Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
Mereo BioPharma (Nasdaq: MREO) and Sentynl Therapeutics agreed an option and license deal giving Sentynl exclusive US commercial rights and global manufacturing rights for alvelestat, a Phase III-ready oral neutrophil elastase inhibitor for alpha-1 antitrypsin deficiency-associated lung disease. Mereo gets an undisclosed option fee and up to $40M in upfront and R&D payments plus tiered royalties; trial initiation targeted for early 2027.
Mereo BioPharma Group plc (MREO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mreo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alph
Over the past 7 days, alphai's AI scored 4 news stories mentioning MREO (Mereo BioPharma Group plc). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent MREO coverage spans financial news, mergers & acquisitions and earnings.
The licensing deal can add near-term cash (option fee and milestones) and de-risk U.S. development funding via partner support.
Deal expands Mereo’s rare-disease monetization while shifting US commercialization to Sentynl; near-term impact is pipeline de-risking and potential cash/royalty visibility.
Near-term trading focus is on runway extension and the probability-weighted funding/timeline for alvelestat Phase 3, alongside setrusumab regulatory path discussions.
The deal expands Mereo’s rights and cash-flow potential for alvelestat, while assigning Mereo leadership of the global Phase 3 and regulatory interactions.
The lawsuit against Mereo BioPharma indicates potential legal and financial risks, likely leading to further stock decline.
alphai scores every news story that mentions MREO with an AI model for sentiment and relevance, and aggregates insider trades from Mereo BioPharma Group plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readMereo BioPharma (Nasdaq: MREO) and Sentynl Therapeutics agreed an option and license deal giving Sentynl exclusive US commercial rights and global manufacturing rights for alvelestat, a Phase III-ready oral neutrophil elastase inhibitor for alpha-1 antitrypsin deficiency-associated lung disease. Mereo gets an undisclosed option fee and up to $40M in upfront and R&D payments plus tiered royalties; trial initiation targeted for early 2027.
4 min readMereo BioPharma Group plc (MREO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mreo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alph
6 min readMereo BioPharma Group plc (MREO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K true false 0001719714 X0 00-0000000 0001719714 dei:AdrMember 2026-08-11 2026-08-11 0001719714 2026-08-11 2026-08-11 0001719714 us-gaap:CommonStockMember 2026-08-11 2026-08-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursu
2 min readBragar Eagel & Squire, P.C. announced a class-action lawsuit against Mereo BioPharma Group plc (NASDAQ:MREO) on behalf of investors who purchased shares between June 5, 2023, and December 26, 2025. The lawsuit alleges that Mereo made misleading statements regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which ultimately failed to meet their primary endpoints, causing a significant stock price decline. Investors have until April 6, 2026, to apply to be lead plaintiff.
3 min readHolzer & Holzer, LLC is reminding investors of the April 6, 2026, lead plaintiff deadlines for several shareholder class action lawsuits. These lawsuits are filed against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE). The firm encourages investors who suffered significant losses during the specified periods to contact them to discuss their legal rights.
1 min readBragar Eagel & Squire, P.C. has reminded investors that class action lawsuits have been filed against Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc. The lawsuits allege that both companies made materially false and misleading statements regarding the Phase III Orbit and Cosmic Studies for setrusumab in patients with Osteogenesis Imperfecta, leading to significant stock price declines when the studies failed to meet primary endpoints. Investors are encouraged to contact the firm by April 6, 2026, to serve as lead plaintiff.
2 min readFaruqi & Faruqi, LLP is investigating potential securities class action claims against Mereo BioPharma Group plc (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff. The investigation follows a significant stock price drop on December 29, 2025, after two Phase 3 studies of setrusumab failed to meet their primary endpoints. Investors who purchased Mereo BioPharma securities between June 5, 2023, and December 26, 2025, and suffered losses are encouraged to contact the firm.
2 min readMereo BioPharma Group (NASDAQ:MREO) experienced unusually large options trading activity on Wednesday, with call option volume increasing by 61% compared to its daily average. The stock's equity trading volume also surged, reaching 28.2 million shares, significantly higher than its average. Analysts currently have a "Hold" consensus rating on MREO, with institutional investors maintaining a significant ownership stake.
2 min readBTIG analyst Julian Harrison has lowered the price target for Mereo BioPharma Group (MREO) from $6.00 to $1.00, an 83.33% decrease, while maintaining a "Buy" rating. This decision reflects continued confidence in the company's long-term prospects despite the significant reduction in the target price. Mereo BioPharma Group is a UK-based biopharmaceutical company specializing in rare disease therapeutics, with key product candidates setrusumab and alvelestat.
2 min read
